Code Bio
Diana Bernstein is a Vice President at Northpond Ventures on the firm’s biotechnologies team. Previously, Diana was a Senior Associate at MRL Ventures Fund, the corporate venture fund of Merck & Co. (NYSE: MRK), investing in early-stage human therapeutics companies. Prior to that, she was an Associate at Flagship Pioneering, leading projects to conceive and build platform-based therapeutics companies. Diana also spent time at Sigma-Tau Pharmaceuticals (now Leadiant Biosciences) and PricewaterhouseCoopers. She received her Ph.D. in pharmacology from University of Pennsylvania, and a B.S. in finance and B.S. in cell biology and molecular genetics from University of Maryland, College Park.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Code Bio
Code Biotherapeutics is an emerging next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases not well served by other gene therapy technologies.